Viatris Inc. (VTRS) News
Filter VTRS News Items
VTRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTRS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VTRS News From Around the Web
Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Is Viatris (VTRS) the Best Medical Stock to Buy Under $20?We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by […] |
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET. |
US FDA restricts imports of some Viatris drugs made at India facilityThe FDA has issued a warning letter to Viatris related to its drug manufacturing facility in Indore in the central Indian state of Madhya Pradesh, the company said, without disclosing the specifics of the warning. The 11 products will no longer be accepted into the U.S. until the warning letter is lifted, Viatris said in a statement. |
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn?We recently compiled a list of the 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other best stocks to buy according to Billionaire David Einhorn. The markets are broken and getting worse. That’s the stance […] |
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet RheumatologyViatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi, showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. Cenerimod was shown to be well tol |
Viatris fined in Morocco over merger notification, sources sayU.S. pharmaceutical giant Viatris Inc has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday. Viatris was formed by the merger of Mylan, which has a subsidiary in Morocco, and Pfizer's Upjohn business in 2020. The fine, equivalent to 2.5% Viatris' revenue in Morocco last year, has already been paid to the Moroccan treasury, the sources said, requesting anonymity. |
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/YTBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance. |
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145mALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, Australia, and China. |
Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...Viatris Inc (VTRS) reports solid financial performance with a focus on innovation and debt management, despite challenges in certain markets. |
S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark RateThe S&P 500 added 0.7% on Thursday Nov. 7, 2024, as the Fed announced a quarter-point interest-rate cut, in line with market expectations. |